Companies the likes of Treasury Wine Estates Ltd (ASX: TWE), Bellamy’s Australia Ltd (ASX: BAL), and A2 Milk Company Ltd (ASX: A2M) have not only performed well but received an extra ‘kick’ on the back of China.
The concept of China’s immense population, growth potential, and demand for baby formula, health and wellness products created an incredibly lucrative investment option for Australian investors.
But, as China’s growth slows and the implementation of tightened examination on Australian exporting companies, is the China dream still alive?
For baby formula companies such as A2 Milk, Bellamy’s and their suppliers such as Fonterra Shareholders’ Fund (ASX: FSF) and Synlait Milk Ltd (ASX: SM1), the process of obtaining Chinese accreditation for exporting can be a hinderance on the bottom line.
With the implementation of requirements such as the State Administration for Market Regulation (SAMR, formerly CFDA) for infant formula and Certification and Accreditation Administration (CNCA), producers can no longer simply export to China.
The progress of obtaining such requirements can be time-consuming. For example, Bellamy’s has been in the process of applying for SAMR for well over a year and adapted its business model to a so-called “China offline channel”.
I believe China will continue to refine its importing policies, particularly on “Daigou” – individuals who export goods back overseas.
At the same time, the baby formula space is becoming crowded with the likes of Wattle Health Australia Ltd (ASX: WHA) and many new entrants such as Australia Health and Nutrition (ASX: AN1) (yet to be listed), Nestle’s new infant formula range and more.
Should you buy A2 Milk or Bellamy’s shares?
I still strongly believe A2 Milk is an incredible company, while Bellamy’s is still going through a transitional phase of obtaining SAMR accreditation and rebranding.
However, in a recent note out of Bell Potter, they seem convinced that analysts and investors have become too enthusiastic about growth prospects for A2 and downgraded them to a sell with a price target of $11.50.
The baby formula sector has arguably transitioned through the explosive growth and hype phase and reverted back to normalised growth and valuation. I see the sector as not a growth play but a value play. Would I buy A2 Milk at today’s prices? No. Would I buy A2 Milk at $10.00? Maybe.
5 stocks under $5
We hear it over and over from investors, "I wish I had bought Altium or Afterpay when they were first recommended by The Motley Fool. I'd be sitting on a gold mine!" And it's true.
And while Altium and Afterpay have had a good run, we think these 5 other stocks are screaming buys. And you can buy them now for less than $5 a share!
*Extreme Opportunities returns as of June 5th 2020
Motley Fool contributor Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended Treasury Wine Estates Limited. The Motley Fool Australia owns shares of A2 Milk. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
- ASX pushed lower on Monday after recession fears trigger global sell-off – March 25, 2019 5:18pm
- Lower yields, falling property and slowing growth putting pressure on ASX bank shares – March 25, 2019 4:34pm
- Is the China dream still alive for the likes of A2 Milk and Bellamy’s? – March 22, 2019 4:21am